GRANULES INDIA LTD.-$

Granules India Limited has submitted its Monitoring Agency Report for the quarter ended June 30, 2026. The report, issued by India Ratings & Research Private Limited, confirms no deviation from the objects for the utilization of proceeds raised through a Preferential Issue. The findings are based on a management undertaking and a statutory auditor certificate dated July 17, 2026, from S.R. Batliboi & Associates LLP. The company secretary and compliance officer, Chaitanya Tummal, digitally signed the filing on July 21, 2026.

Granules India Ltd. announced its unaudited financial results for the first quarter of FY27, reporting a significant 22% year-on-year growth in revenue from operations to INR 14,768 Mn. EBITDA surged by 37% YoY to INR 3,389 Mn, and Profit After Tax (PAT) increased by a substantial 60% YoY to INR 1,800 Mn. The company highlighted improved ROCE to 18.0% and a reduced net debt of INR 1,012 Mn. Management expressed confidence in sustainable growth, driven by a focus on regulatory excellence, portfolio transformation, and strategic investments in R&D and digitalization.

Granules India Limited announced that its Board of Directors met on July 21, 2026, to approve the unaudited financial results for the first quarter ended June 30, 2026. The results, prepared under Indian Accounting Standards (Ind AS), were presented on both a standalone and consolidated basis. The company also submitted the Limited Review Report from its statutory auditors, S.R. Batliboi & Associates LLP, as required by SEBI Listing Regulations. The board meeting commenced at 10:15 AM and concluded at 12:00 PM.

Granules India Ltd has published its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26. The report details the company's commitment to environmental stewardship, social responsibility, and governance, aligning with SEBI regulations. Key achievements highlighted include CDP ratings (A List for Climate Change, B for Water Security, B- for Forests), a Gold rating from EcoVadis (top 5% globally), and an S&P Global ESG Score of 62/100. The company also achieved Zero Waste to Landfill certification for its Gagillapur unit and received sustainability awards from Haleon and CII. Granules India reaffirmed its commitment to UN-WEP, PSCI, UN Global Compact, and has set a Net Zero target by 2050 approved by SBTi.

Granules India Limited has submitted its Integrated Annual Report for the financial year 2025-26, in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report, titled 'Where Strategy Meets Evolving Healthcare Needs, Science & Sustainability,' details the company's transformation into a science-led pharmaceutical entity. It covers corporate overview, management's message, business strategy, financial statements (standalone and consolidated), and statutory reports including the Business Responsibility and Sustainability Report. The report also includes the Notice of the 35th Annual General Meeting, scheduled for August 06, 2026, to be held via Video Conferencing. The documents are available on the company's website and are being disseminated to shareholders.

Granules India Ltd has announced its 35th Annual General Meeting (AGM) scheduled for August 6, 2026, at 11:30 AM IST. The meeting will be conducted via Video Conferencing. The company has submitted its Integrated Annual Report for the financial year 2025-26, in compliance with SEBI regulations. This report, detailing the company's strategy, business overview, financial statements, and sustainability efforts, is available on the company's website and has been sent to shareholders. The report emphasizes Granules India's transformation into a science-led, globally competitive pharmaceutical company focused on innovation, quality, and sustainable growth.

Granules India Ltd has announced that its Board of Directors will convene on July 21, 2026. The primary agenda item for this meeting is to consider and approve the unaudited financial results for the first quarter ended June 30, 2026. In conjunction with this announcement, the company has also stated that the trading window for its securities will remain closed until July 23, 2026, to prevent insider trading.

Granules India Limited has announced it secured Sole First-to-File (FTF) status for its Abbreviated New Drug Application (ANDA) for Sodium Oxybate Extended-Release for Oral Suspension. This is the generic equivalent of LUMRYZ® extended-release oral suspension. This marks Granules' second Sole FTF ANDA, following Amphetamine Extended-Release Tablets. The company views this as a significant milestone in its complex generics journey, highlighting its R&D and regulatory capabilities. The drug is indicated for narcolepsy treatment in the US. This achievement reinforces Granules' focus on innovation and expanding its differentiated portfolio in regulated markets.

Granules India Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is effective from July 01, 2026, and will remain in effect until 48 hours after the declaration of the un-audited financial results for the first quarter of FY27, ending on June 30, 2026. The measure aligns with SEBI (Prohibition of Insider Trading) Regulations 2015 and the company's internal code of conduct, aimed at preventing insider trading.

Granules India Limited announced that its wholly-owned subsidiary, Granules Pharmaceuticals, Inc. (GPI), has received the Establishment Inspection Report (EIR) from the US FDA for its Chantilly, Virginia facility. The facility received a Voluntary Action Indicated (VAI) classification following an inspection conducted from March 30 to April 3, 2026, where four Form 483 observations were issued. This facility is crucial to Granules' global manufacturing and supply network, with a focus on quality and regulatory compliance.